Lucid Diligence Brief: Regeneron Otarmeni FDA approval
Lucid Diligence Brief: Regeneron Otarmeni FDA approval Professional audiences…
Lucid Diligence Brief: Avalyn Pharma IPO
Lucid Diligence Brief: Avalyn Pharma IPO Professional audiences only. Not…
Lucid Diligence Brief: Merck × Google Cloud agentic AI partnership
Lucid Diligence Brief: Merck × Google Cloud agentic AI partnership Professional…
Lucid Diligence Brief: Eli Lilly acquires Kelonia for up to $7 billion in cash
Lucid Diligence Brief: Eli Lilly acquires Kelonia for up to $7 billion in cash…
Lucid Diligence Brief: MeiraGTx re-acquires bota-vec rights from J&J
Lucid Diligence Brief: MeiraGTx re-acquires bota-vec rights from J&J…
Lucid Diligence Brief: Vir Biotechnology $1.37B collaboration with Astellas
Lucid Diligence Brief: Vir Biotechnology $1.37B collaboration with Astellas…
Lucid Diligence Brief: Eli Lilly acquires Centessa Pharmaceuticals
Lucid Diligence Brief: Eli Lilly acquires Centessa Pharmaceuticals Professional…
Lucid Diligence Brief: Ambrosia Biosciences $100M Series B for oral GLP-1 asset
Lucid Diligence Brief: Ambrosia Biosciences $100M Series B for oral GLP-1……
Lucid Diligence Brief: Royalty Pharma and J&J partner in a $500M R&D deal for JNJ-4804
Lucid Diligence Brief: Royalty Pharma and J&J partner in a $500M R&D…
Lucid Diligence Brief: Otsuka to acquire Transcend Therapeutics
Lucid Diligence Brief: Otsuka to acquire Transcend Therapeutics Professional…
Lucid Diligence Brief: AstraZeneca's tozorakimab meets primary endpoint in COPD
Lucid Diligence Brief: AstraZeneca's tozorakimab meets primary endpoint in……
Lucid Diligence Brief: MSD to acquire Terns
Lucid Diligence Brief: MSD to acquire Terns Professional audiences only. Not…